Alethia Young

Ms. Young has over 20 years of experience in biopharmaceutical industry. Currently, Ms. Young is the chief financial officer at Graphite Bio. In this role, Ms. Young oversees the company’s finance, investor relations and corporate communications functions, and plays a key role in overall corporate strategy.

Previously Ms. Young served as senior biotech analyst and head of research at Cantor Fitzgerald, managing the equity research department covering large cap and small-mid-cap biotechnology companies. Prior to joining Cantor Fitzgerald in 2018, Ms. Young held senior biotech analyst positions at Credit Suisse and Deutsche Bank. Earlier in her career, she was a research policy analyst and president at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan in the investment banking and asset management divisions.

Ms. Young earned a B.A. in Economics and Spanish from Duke University. She currently serves on the board of directors for BUILD NYC.